This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Magdalina (Lina) Gugucheva
Magdalina (Lina) Gugucheva
New York +1 212 841 1051 Download V-card

Lina Gugucheva is a corporate associate resident in the firm’s New York office.  Ms. Gugucheva focuses on strategic licensing, collaboration and other intellectual property arrangements for the firm’s life sciences, healthcare and technology clients -- a practice in which she leverages her background in molecular biology as well as her lifetime passion for science.  In addition, Ms. Gugucheva regularly advises on the corporate, IP, commercial and regulatory aspects of various other business transactions including venture capital financings, strategic investments and M&A deals.  She also maintains an active pro bono practice advising non-profit clients pursuing technology, arts and entrepreneurship causes, and is a regular contributor to the Covington eHealth blog.

  • Innovacell on its collaboration and licensing agreement with Norgine for Europe (excluding Russia and Turkey), SADC and MENA regions in which Innovacell and Norgine will co-develop, and Norgine will commercialize, ICEF15 - an innovative personalized cell therapy to treat fecal incontinence.
  • A major European pharmaceutical company in connection with its exclusive in-license and distribution agreement for a fertility diagnostic device system and related software.
  • Johnson & Johnson Development Corporation in preferred stock investments in various start-up biotechnology companies.
  • Forest Laboratories in its $1.1 billion acquisition of Furiex Pharmaceuticals and its $415 million sale of milestone and royalty payments on two drugs, alogliptin and Priligy®, to Royalty Pharma.
  • AstraZeneca in its acquisition of Bristol-Myers Squibb's interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments.
  • MedImmune, AstraZeneca’s global biologics research and development arm, on the FDA regulatory and intellectual property aspects of its acquisition of Amplimmune for $225 million upfront and additional potential milestone payments.
  • Salix Pharmaceuticals on the commercial and intellectual property aspects of its $2.6 billion acquisition of Santarus, Inc.
  • Actelion Ltd. on the FDA regulatory and commercial aspects of its acquisition of Ceptaris Therapeutics for $250 million upfront and additional potential payments based on net product sales and achieving milestones.
  • A major medical device company in its asset purchase and in-license of intellectual property related to a surgical device, including regulatory advice regarding reimbursement-linked milestones.

Pro Bono

  • Sabin Vaccine Institute in negotiating certain manufacturing and supply arrangements in support of its clinical trial program.
  • Coalition for Queens, a not-for-profit corporation fostering a tech entrepreneurial ecosystem in the borough of Queens in New York City, with various corporate, intellectual property, technology, privacy and transactional matters.
  • Alliance for the Arts, Inc., an arts education not-for-profit in connection with its corporate dissolution and the transfer of its intellectual property and technology assets.
  • Eyebeam, an art and technology center that promotes digital research and experimentation among artists, technologists and the public, on intellectual property and corporate matters.
  • Lawyers Alliance for New York in connection with advice to its member organizations regarding federal health information privacy rules, including HIPAA and the HITECH Act.

Previous Experience

  • Presidential Commission for the Study of Bioethical Issues (2011)